• Species Reactivity

  Human

• Specificity

  Detects human JAM-A in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) JAM-B, recombinant mouse (rm) JAM-A, or rmJAM-4 is observed.

• Source

  Monoclonal Mouse IgG1 Clone # 654806

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human JAM-A    
  Ser28-Ala242 (predicted)    
  Accession # Q9Y624

• Formulation

  Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

• Label

  Alexa Fluor 594

Applications

• 
  

  Recommended    
  Concentration

  Sample

• Flow Cytometry

  0.25-1 μg/10    ⁶ cells

  MCF?7 human breast cancer cell line

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Shipping

  The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

• Stability & Storage

  Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: JAM-A

The family of junctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial or epithelial cells. Some family members are also found on blood leukocytes and platelets. Human JAM-A, also known as platelet adhesion molecule 1 (PAM-1) and platelet F11 receptor (3), is predominantly expressed at intercellular junctions of both epithelial cells and endothelial cells (1 - 4). It is also expressed on circulating blood cells including neutrophils, monocytes, platelets, erythrocytes and lymphocytes (5). Human JAM-A cDNA predicts a 299 amino acid (aa) residue precursor protein with a putative 27 aa signal peptide, a 210 aa extracellular region containing two Ig-like V-subset domains, a 24 aa transmembrane domain and a 38 aa cytoplasmic domain. The human and mouse proteins share approximately 67% aa sequence homology. Human JAM-A also shares approximately 35% and 32% aa sequence homology with human JAM-B and JAM-C, respectively. JAM-A exhibits homophilic interactions to regulate tight junction assembly and modulate paracellular permeability. This homophilic interation also mediates platelet aggregation and adhesion to endothelial cells and may play a role in thrombosis (3). JAM-A binds heterotypically with the beta 2 integrin lymphocyte function-associated antigen-1 (LFA-1). This JAM-A-LFA-1 interaction is involved in leukocyte adhesion and transmigration (6). JAM-A has also been shown to bind reovirus attachment protein sigma-1 to permit reovirus infection and signal virus-induced apoptosis (7).

• References:

1. Chavakis, T. et al. (2003) Thromb. Haemost. 89:13.

2. Aurand-Lions, M. et al. (2001) Blood 98:3699.

3. Sobocka, M.B. et al. (2000) Blood 95:2600.

4. Martin-Padura, I. et al. (1998) J. Cell Biol. 142:117.

5. Williams, L.A. et. al. (1999) Mol. Immunol. 36:1175.

6. Ostermann, G. et al. (2002) Nature Immunol. 3:151.

7. Barton, E.S. et al. (2001) Cell 104:441.

• Long Name:

  Junctional Adhesion Molecule A

• Entrez Gene IDs:

  50848 (Human); 16456 (Mouse)

• Alternate Names:

  CD321 antigen; CD321; F11 receptor; F11R; JAM-1; JAM1CD321; JAMA; JAM-A; JCAMJAM; Junctional adhesion molecule 1Platelet F11 receptor; junctional adhesion molecule A; PAM-1; PAM-1KAT; Platelet adhesion molecule 1